Epizyme gains on latest tazemetostat readout in NHL

Epizyme Inc. (NASDAQ:EPZM) gained $1.20 (11%) to $12.35 on Wednesday as investors digested updated results from a Phase II trial of tazemetostat (EPZ-6438) in patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) or follicular lymphoma.

Compared with data from the same study that were released in an abstract last week, the new results showed that tazemetostat led to a higher overall response rate (ORR) among follicular lymphoma patients with enhancer of zeste homolog 2 (EZH2) mutations, but a lower ORR among DLBCL patients with the mutation. Tazemetostat is a selective inhibitor of EZH2...